Roche and Spanish firm Oryzon Genomics have teamed up to develop epigenetics-based medicines, in a deal that could see the Swiss big pharma pay out more than $500m in potential milestones.
Roche and Spanish firm Oryzon Genomics have teamed up to develop epigenetics-based medicines, in a deal that could see the Swiss big pharma pay out more than $500m in potential milestones.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
